EMA approves TX01 PIP, unlocking the PUMA pathway for Theranexus and Exeltis
Decision brief
Answer first · skim in under a minute
THX Pharma (Theranexus) and Exeltis have secured EMA approval of the paediatric investigation plan (PIP) for TX01. The decision unlocks the PUMA registration pathway and is tied to 10 years of European market protection in Niemann-Pick type C disease.
THX Pharma (Theranexus) and Exeltis said EMA’s Paediatric Committee issued a positive opinion on the paediatric investigation plan for TX01 in Niemann-Pick type C disease, clearing a required gate for a future Paediatric Use Marketing Authorisation (PUMA) filing in the European Union.
Contents9 sections
Key Takeaways
- A PIP is EMA’s required paediatric development plan supporting authorisation of medicines for children.
- An agreed PIP is a prerequisite before a PUMA marketing application can be filed.
- Partners state PDCO’s positive opinion on TX01 for Niemann-Pick type C unlocks the PUMA pathway, with a planned Exeltis filing in Q1 2027.
- PUMA can deliver up to 10 years of paediatric market protection and a centralised authorisation across the EU plus EEA states if granted.
What is the European paediatric investigation plan?
EMA defines a paediatric investigation plan as a development plan aimed at ensuring that the necessary data are obtained through studies in children to support authorisation of a medicine for paediatric use.
Primary agency guidance is on the EMA paediatric investigation plans page.
How does PIP approval unlock the PUMA pathway?
PUMA is the EU’s dedicated marketing authorisation route for medicines developed exclusively for paediatric use based on active substances already authorised in adults. An agreed PIP is a regulatory prerequisite for PUMA submission.
EMA’s overview of paediatric medicines and PUMA incentives is summarized under its paediatric medicines research and development hub.
- Centralised assessment possible across EU Member States
- Potential paediatric market protection of up to 10 years if PUMA is granted
- PIP agreement does not itself equal marketing authorisation
What changed for TX01 according to the sponsors?
On June 9, 2026, THX Pharma and Exeltis announced that EMA, through PDCO, issued a positive opinion on the TX01 PIP in Niemann-Pick type C disease and that the subsequent EMA Decision confirms alignment with European paediatric standards.
The companies said Exeltis plans to file the PUMA application in the first quarter of 2027 and that a granted PUMA would support a single authorisation valid across all 27 EU Member States plus Iceland, Liechtenstein and Norway. Those company-stated timelines are commercial plans, not an EMA approval of TX01.
Why does this matter for investors and BD teams?
For rare paediatric metabolic diseases, PIP clearance is often the gating item before partners commit to a PUMA dossier. The announcement therefore de-risks regulatory sequencing more than it proves efficacy. Commercial exclusivity of up to 10 years would apply only if PUMA is ultimately granted.
Related background reading on EU paediatric regulation context is available via EUR-Lex for the Paediatric Regulation framework.
What remains unproven?
A positive PIP opinion is not a marketing authorisation, not an EMA endorsement of clinical benefit, and not a guarantee that the Q1 2027 filing or a 2027 launch will occur. Efficacy, safety, and benefit–risk for TX01 remain subject to the future PUMA review dossier.
Related NovaPharma coverage
- CHMP backs nerandomilast for IPF and PPF in EU
- Europe Drug Prices Face Pressure as U.S. Benchmarking Tightens
- FDA Drug Approval: What Approval Means for Pharma Marketing and BD
Frequently Asked Questions
What is a paediatric investigation plan (PIP)?
A paediatric investigation plan is a development plan aimed at ensuring that the necessary data are obtained through studies in children to support the authorisation of a medicine for paediatric use, as defined by the European Medicines Agency.
Why does a PIP matter for a PUMA filing?
An agreed PIP is a regulatory prerequisite for submitting a Paediatric Use Marketing Authorisation (PUMA). PUMA is a dedicated EU route for medicines developed exclusively for paediatric use based on active substances already authorised in adults.
What did THX Pharma and Exeltis announce for TX01?
The partners said EMA’s Paediatric Committee issued a positive opinion on the TX01 PIP in Niemann-Pick type C disease, unlocking a PUMA registration pathway, with Exeltis planning to file in the first quarter of 2027.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for TX01.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
